Mazdutide
A weekly GLP-1 and glucagon dual agonist developed by Innovent with Eli Lilly. Approved in China in 2025 for weight management.
- Evidence
- Ongoing clinical research
- Half-life
- Days
- Sources
- 2 cited
Is mazdutide FDA-approved?
Approved in China (2025). Not FDA-approved.
Overview
In the 48-week GLORY-1 phase 3 trial in Chinese adults with overweight or obesity, average weight loss was about 11% and 14% on the two doses, versus no change on placebo. Trials in type 2 diabetes and head-to-head against semaglutide are ongoing.
How it works
Like survodutide, it pairs GLP-1 action (less appetite, slower stomach) with glucagon action (more energy use and liver fat burning).
How long does mazdutide stay in the body?
Long enough for once-weekly shots in trials.
What it's studied for
- Weight management
- Type 2 diabetes
- Fatty liver
Reported side effects
- Nausea, diarrhea, vomiting (mostly mild to moderate)
- Higher heart rate
Related: Survodutide, Orforglipron, CagriSema, Amycretin.
Sources
The studies and prescribing labels this page is written from.
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1). N Engl J Med, 2025 PubMed
- A phase 2 trial of mazdutide in Chinese adults with overweight or obesity. Nat Commun, 2023 PubMed
